ORAGRAFIN CALCIUM Drug Patent Profile
✉ Email this page to a colleague
When do Oragrafin Calcium patents expire, and what generic alternatives are available?
Oragrafin Calcium is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in ORAGRAFIN CALCIUM is ipodate calcium. There is one drug master file entry for this compound. Additional details are available on the ipodate calcium profile page.
Summary for ORAGRAFIN CALCIUM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 8 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ORAGRAFIN CALCIUM at DailyMed |
US Patents and Regulatory Information for ORAGRAFIN CALCIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | ORAGRAFIN CALCIUM | ipodate calcium | GRANULE;ORAL | 012968-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |